The text discusses the screening for DPD deficiency in patients receiving fluoropyrimidine-based chemotherapies, the significance of tumor budding in solid cancers, the number of nodes needed to accurately stage T1 and T2 colon cancers, the efficacy of adjuvant chemotherapy in Dukes' B versus Dukes' C colon cancer, the incidence and patterns of recurrence after resection for colonic cancer, the clinical utility of colon cancer molecular subtypes, and the benefit of adjuvant chemotherapy in older patients with colon cancer.